Quick Answer
Oncotelic Therapeutics, Inc. reported Revenue (ASC 606) of $1.74 million for fiscal year 2020.
Oncotelic Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2020 | $1.74M | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| June 30, 2020 | $1.40M | — | +310.7% |
| March 31, 2020 | $340.9K | — | — |
- The most recent figure is from Oncotelic Therapeutics, Inc.’s fiscal year 2021 report (Form 10-K), filed with the SEC on April 15, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: